Navigation Links
Rescuing injured hearts by enhancing regeneration

Using a two-drug approach, researchers at Children's Hospital Boston have demonstrated that it may be possible to rescue heart function after a heart attack and protect the heart from scarring. Working with rats, they combined an agent that overcomes a natural inhibitor of cell division with a naturally occurring growth factor that encourages blood vessel growth (angiogenesis). Together, these two agents enabled heart-muscle cells to multiply and the heart to regain its function after a simulated myocardial infarction. The study will appear in the October 17 issue of the Proceedings of the National Academy of Sciences (posted online during the week of October 9).

Normally, after a heart attack, the damaged heart muscle cannot grow back and is instead replaced by scar tissue. Excessive scarring can impair the heart's pumping capacity and can lead to life-threatening arrhythmias. Heart-muscle cells (cardiomyocytes) normally cannot replicate in mammals, a major obstacle to regeneration. However, in a paper last year, Felix Engel, PhD, and Mark Keating, MD, in the Department of Cardiology at Children's Hospital Boston, showed that they could coax cardiomyocytes to multiply in a petri dish by inhibiting an enzyme known as p38 MAP kinase, which normally suppresses cardiomyocyte replication. [See: www.childrenshospital.org/newsroom/Site1339/mainpageS1339P1sublevel139.html]

Engel and Keating (Keating is now at the Novartis Institute for BioMedical Research) now build on this finding. They studied 120 rats, some with simulated heart attacks. After the injury, the animals were randomly assigned to receive injections with a p38 MAP kinase inhibitor alone, the angiogenesis stimulator FGF1 alone, both agents together, or saline (placebo) for four weeks. Three months later, rats that had received both FGF1 and the p38 MAP kinase inhibitor had markedly improved heart
'"/>

Source:Children's Hospital Boston


Page: 1 2 3

Related biology news :

1. Molecular messengers perform a crucial role in the ability of injured nerve cells to heal themselves
2. NASA technology helping injured US troops
3. Bone marrow stem cells may heal hearts even years after heart attacks
4. Mice with glowing hearts shed light on how hearts develop
5. Free-radical busting antioxidants might not promote healthy hearts
6. UT Southwestern researchers find gene mutation that leads to broken hearts
7. Adult stem cell research at UB targets damaged hearts
8. Newts which regrow their hearts
9. Mechanical artificial hearts can remove need for heart transplant by returning heart to normal
10. Mutation improves memory, may lead to memory-enhancing pill
11. Researchers feed tiny pills of RNA to planarians to identify genes essential for regeneration

Post Your Comments:
(Date:11/4/2009)...,, CARLSBAD, Calif., Oct. 23 Ge...ure biosample management for genomic discovery, me...vid Wellis, Ph.D., GenVault,s President and CEO, w...e taking place on October 26th and 27th in La Joll...ill provide an overview of the company together wi...
(Date:11/4/2009)...,, NEW YORK, Oct. 27 Global Rai...mpany and advanced R&D laboratory, today annou...e and is prepared to actively commercialize its su...dge biometric security offerings. ,, During the...llions of dollars to develop and deploy a series o...
(Date:11/4/2009)...,, CARLSBAD, Calif., Nov. 4 Gen...hat William Brody, M.D., Ph.D., has joined its Boa...idential Chair of the Salk Institute, is an acclai...ior to joining the Salk Institute, Dr. Brody serve...e is a member of the National Academy of Engineeri...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Secretary Shinseki Moves to Simplify PTSD Compensation Rules 55136 1Secretary Shinseki Moves to Simplify PTSD Compensation Rules 55136 2Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 1Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 2Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 3Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 4IDEV 28R 29 Technologies Announces First Patient Enrolled in Multi Center Clinical Trial of SUPERA 28R 29 PERipheral Stent 4886 1IDEV 28R 29 Technologies Announces First Patient Enrolled in Multi Center Clinical Trial of SUPERA 28R 29 PERipheral Stent 4886 2
...mall molecules containing platinum, Virginia Commo...s have created a process to inhibit a class of pro...may help researchers develop new drugs to fight HI...n as zinc fingers. , In the May 30 issue of the j...ed that a zinc finger protein, known as HIV NCp7, ...
...earcher Zafira CastaƱo has discovered that the los...favors tumor growth. This was the conclusion that ...tion which she defended at the University of Navar...h prior studies from her laboratory, which demonst...cells that coat the normal lung, and which, nevert...
...ty crayfish - a voracious, bullying exotic that ha...akes - may have finally met its match. , Since it... 1950s, the crayfish has spread to thousands of la...sts that are critical fish habitat, evicting the n...r and scooping up fish eggs like so much caviar. ...
Other Biology News:New protein target may advance design of HIV and cancer drugs 2Study shows hope for ridding lakes of clawed invader 2Study shows hope for ridding lakes of clawed invader 3
(Date:11/6/2009)...PRNewswire-FirstCall/ -- BioSpecifics Technologies...ny developing first-in-class collagenase-based pro...he third quarter ended September 30, 2009. ,, ...s year, the FDA,s Arthritis Advisory Committee una...val of XIAFLEX(TM) for the treatment of Dupuytren,...
(Date:11/6/2009)...ov. 6 Calbiotech, Inc. announced t...ovative Research (SBIR) Phase I contract by the U....er terms of the agreement, Calbiotech will develop...s of Dengue virus. ,, Dengue virus is a mosq...t to military forces deployed to tropical areas of...
(Date:11/5/2009)...5 GenVec, Inc. (Nasdaq: ...the third quarter ended September 30, 2009. GenVec...are) for the three months ended September 30, 2009... share) in the comparable quarter of 2008. For the...t loss was $14.1 million ($0.15 per share), compar...
(Date:11/5/2009)...day, November 5, 2009 at 4:30 p.m. Eastern Time ,...FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("Onc...eported unaudited financial results for the third ...nd reviewed the Company,s highlights for the third... results reflect the operations of OncoGenex Techn...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...s., Oct. 31 Idenix,Pharmaceuticals, Inc., (Nasdaq...financial results for the third quarter of 2007 on... markets close. In conjunction with the issuance ...a conference call at 4:30 p.m. ET on Tuesday, Nove...sults for the third quarter,2007. To access the c...
...ct. 31 Modigene Inc. (OTC,Bulletin Board: MODG) t...,at the Acumen BioFin Rodman & Renshaw 9th Annual ...07 at 1:40 pm ET. The conference will be held at,t...ne CEO Abraham Havron and President Shai Novik wil...ew and review of corporate,developments. The pres...
.... 31 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS )...n,BioFin(TM) Rodman & Renshaw 9th Annual Healthcar...p.m. EST (1:25 p.m. PST). The conference is being,... Ph.D., President and Chief Executive Officer of A...ew of Anadys and its two,development-stage product...
Other Biology Technology:Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference 2
Mycoplasma IgG ELISA Kit, Single from Bio-Quant Inc.
Methadone ELISA Kit, Single from Bio-Quant Inc.
Rat Prolactin EIA Kit from Cayman Chemical
Z Amphetamine ELISA Kit, Single from Bio-Quant Inc.
Biology Products: